Since 2006 Kevin has been working on metabolic imaging with hyperpolarised 13C-labelled cell substrates to detect treatment response in tumours. He leads the C2Am project.
June 16, 2020
Since 2006 Kevin has been working on metabolic imaging with hyperpolarised 13C-labelled cell substrates to detect treatment response in tumours. He leads the C2Am project.
The Mark Foundation Institute for Integrated Cancer Medicine (MFICM) at the University of Cambridge aims to revolutionise cancer care by affecting patients along their treatment pathway.
